UK psychedelic medicines developer Beckley Psytech has said its candidate for treatment-resistant depression has enhanced the effect of standard antidepressants in a phase 2 trial.

FDA advisors voted against the use of Lykos Therapeutics’ MDMA-based therapy for PTSD, in a first regulatory test for the emerging psychedelics sector ...